CZ165693A3 - 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds - Google Patents

5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds Download PDF

Info

Publication number
CZ165693A3
CZ165693A3 CS931656A CS165693A CZ165693A3 CZ 165693 A3 CZ165693 A3 CZ 165693A3 CS 931656 A CS931656 A CS 931656A CS 165693 A CS165693 A CS 165693A CZ 165693 A3 CZ165693 A3 CZ 165693A3
Authority
CZ
Czechia
Prior art keywords
group
compound
indol
formula
hydrogen
Prior art date
Application number
CS931656A
Other languages
Czech (cs)
English (en)
Inventor
Jolanta T Nowakowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CZ165693A3 publication Critical patent/CZ165693A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CS931656A 1991-02-12 1992-02-03 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds CZ165693A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12
PCT/US1992/000556 WO1992013856A1 (en) 1991-02-12 1992-02-03 5-heteroyl indole derivatives

Publications (1)

Publication Number Publication Date
CZ165693A3 true CZ165693A3 (en) 1994-05-18

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
CS931656A CZ165693A3 (en) 1991-02-12 1992-02-03 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds

Country Status (24)

Country Link
EP (1) EP0571471B1 (cg-RX-API-DMAC7.html)
JP (1) JPH07121942B2 (cg-RX-API-DMAC7.html)
KR (1) KR930703305A (cg-RX-API-DMAC7.html)
AT (1) ATE135005T1 (cg-RX-API-DMAC7.html)
AU (1) AU655456B2 (cg-RX-API-DMAC7.html)
CA (1) CA2101521A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ165693A3 (cg-RX-API-DMAC7.html)
DE (1) DE69208868T2 (cg-RX-API-DMAC7.html)
DK (1) DK0571471T3 (cg-RX-API-DMAC7.html)
ES (1) ES2084347T3 (cg-RX-API-DMAC7.html)
FI (1) FI933551A0 (cg-RX-API-DMAC7.html)
GR (1) GR3019778T3 (cg-RX-API-DMAC7.html)
HU (1) HUT65766A (cg-RX-API-DMAC7.html)
IE (1) IE920442A1 (cg-RX-API-DMAC7.html)
IL (1) IL100888A0 (cg-RX-API-DMAC7.html)
MX (1) MX9200569A (cg-RX-API-DMAC7.html)
MY (1) MY131298A (cg-RX-API-DMAC7.html)
NO (1) NO932859L (cg-RX-API-DMAC7.html)
NZ (1) NZ241584A (cg-RX-API-DMAC7.html)
PT (1) PT100114A (cg-RX-API-DMAC7.html)
TW (1) TW263508B (cg-RX-API-DMAC7.html)
WO (1) WO1992013856A1 (cg-RX-API-DMAC7.html)
YU (1) YU13792A (cg-RX-API-DMAC7.html)
ZA (1) ZA92969B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (cg-RX-API-DMAC7.html) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
JPH10501212A (ja) * 1994-05-19 1998-02-03 メルク シヤープ エンド ドーム リミテツド ５−ｈｔ▲下１ｄ▼−アルファ作働薬としてのインドール−３−イルアルキルのピペラジン、ピペリジンおよびテトラヒドロピリジン誘導体
DE69521895T2 (de) * 1994-06-01 2002-04-04 Astrazeneca Ab, Soedertaelje Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
TR199700993T1 (xx) * 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DK1068198T3 (da) * 1998-03-09 2003-09-22 Lundbeck & Co As H 5-Heteroarylsubstituerede indoler
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
CA2370147C (en) * 1999-04-21 2009-07-28 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
CA2422717A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
MXPA05005701A (es) 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil indoles sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
SI1883451T1 (sl) 2005-04-13 2011-04-29 Neuraxon Inc Substituirane indolne spojine z NOS inhibitorno aktivnostjo
EA016300B1 (ru) * 2005-07-29 2012-04-30 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
EP2010527B1 (en) 2006-04-13 2013-08-14 Neuraxon Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
US20100222345A1 (en) * 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
KR20100103799A (ko) 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
AU2013259737A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
JP6242868B2 (ja) 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
EP3110429A4 (en) 2014-02-27 2018-02-21 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3256450B1 (en) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
MX2017016134A (es) 2015-06-11 2018-08-15 Lycera Corp Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
WO2017075185A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
US5399574A (en) * 1990-06-07 1995-03-21 Burroughs Wellcome Co. Indolyl tetrahydropyridines for treating migraine

Also Published As

Publication number Publication date
MY131298A (en) 2007-08-30
FI933551A7 (fi) 1993-08-11
ZA92969B (en) 1993-08-11
DK0571471T3 (da) 1996-04-01
NO932859D0 (no) 1993-08-11
PT100114A (pt) 1993-05-31
CA2101521A1 (en) 1992-08-13
DE69208868T2 (de) 1996-10-17
NO932859L (no) 1993-08-11
IE920442A1 (en) 1992-08-12
ES2084347T3 (es) 1996-05-01
FI933551L (fi) 1993-08-11
JPH06500122A (ja) 1994-01-06
AU1263792A (en) 1992-09-07
NZ241584A (en) 1994-12-22
JPH07121942B2 (ja) 1995-12-25
IL100888A0 (en) 1992-11-15
WO1992013856A1 (en) 1992-08-20
ATE135005T1 (de) 1996-03-15
GR3019778T3 (en) 1996-07-31
EP0571471B1 (en) 1996-03-06
HUT65766A (en) 1994-07-28
HU9302328D0 (en) 1993-10-28
KR930703305A (ko) 1993-11-29
EP0571471A1 (en) 1993-12-01
YU13792A (sh) 1994-11-15
FI933551A0 (fi) 1993-08-11
AU655456B2 (en) 1994-12-22
TW263508B (cg-RX-API-DMAC7.html) 1995-11-21
DE69208868D1 (de) 1996-04-11
MX9200569A (es) 1992-08-01

Similar Documents

Publication Publication Date Title
CZ165693A3 (en) 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds
US5409941A (en) 5-heteroyl indole derivatives
CN1122032C (zh) 用于治疗心血管疾病的新的取代吡唑衍生物
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CA2169179C (en) 5-arylindole derivatives
AU671836B2 (en) Fused imidazole and triazole derivatives as 5-HT1 receptor agonists
CZ283001B6 (cs) 5-Arylindolové deriváty, meziprodukty pro jejich výrobu a famaceutické prostředky na jejich bázi
EP0773942A1 (en) 4-indole derivatives as serotonin agonists and antagonists
BG60402B2 (bg) Заместени бициклични съединения
JP2010532748A (ja) カルシウムチャネル遮断薬としての２−置換インドール誘導体
CN102224154A (zh) 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
SK105294A3 (en) Indole derivatives, method of their preparation, intermediates of this process, pharmaceutical agents containing these derivatives and use of these derivatives
CS85692A3 (en) 6-HETEROCYCLO-4-AMINO-1,3,4,5-TETRAHYDROBENZO(cd)INDOLE
CA1337202C (en) Cyclic amides which are leukotriene antagonists
EP0227241A2 (en) Medicinal indole and indazole keto sulphone derivatives
US5607957A (en) Imidazole, triazole and tetrazole derivatives
US5510359A (en) Heteroaromatic 5-hydroxytryptamine receptor agonists
JPH0378854B2 (cg-RX-API-DMAC7.html)
AU673098B2 (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
US5521188A (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
FR2761070A1 (fr) Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US5047402A (en) Cyclic amides as medicaments
HK1024243A (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
HK1023119B (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases